The Global Monoclonal Antibodies (mAbs) Market value is projected to reach US$ 289.24 Bn. at the end of the forecast period and it is expected to grow at the CAGR of 7%. The growth is coupled with Increasing R&D activities in genomics coupled with the advent of technologically advanced genetic platforms, such as next-generation sequencing, pose as the major drivers. In addition, the cost-effective nature of the technology is supporting its incorporation in performing research studies to develop mAbs. These are widely accepted biologics and are expected to present a billion-dollar opportunity to pharmaceutical manufacturers over the forecast period.To know about the Research Methodology :- Request Free Sample Report Growing awareness levels amongst patients and physicians pertaining to the applications of mAb therapy are contributing to further growth. Moreover, approval of blockbuster mAbs for a variety of indications is expected to boost the usage rates over the forecast period. For instance, significant revenue generating drugs such as Avastin, Herceptin, Remicade, and Rituxan with FDA approval for an array of conditions (cancer, rheumatoid arthritis, Crohn's disease, ulcerative colitis etc.) further boost the patient base. Global Monoclonal Antibodies (mAbs) Market is predicted to grow at a lucrative CAGR due to the presence of a strong product pipeline. North America had the highest market share in 2017. The Global Monoclonal Antibodies (mAbs) Market is driven by the presence of well-established healthcare infrastructure. Moreover, increasing government funding for cancer research and technology development is anticipated to boost the development of therapeutic proteins over the forecast period. Government support in infection control & management, rising incidence of lifestyle-associated diseases, and the escalating population number are other crucial factors aiding the growth of this sector. Asia Pacific region is expected to exhibit considerable growth owing to rising disposable income, the presence of huge untapped potential, increased expenditure in research & development, and growing patient awareness pertaining to the therapeutic use of mAbs. In vivo technology is cost effective as compared to in vitro production techniques and is preferred for the high concentration of mAbs obtained through this method. However, the availability of several in vitro methods is expected to hamper the adoption of in vivo production techniques in the coming years. The associated benefits of employing in vitro methods for antibody generation, including time efficiency, economic viability, and large-scale production, are anticipated to fuel the segment growth over the forecast period. The report includes the analysis of impact of COVID-19 lock-down on the revenue of market leaders, followers, and disrupters. Since lock down was implemented differently in different regions and countries, impact of same is also different by regions and segments. The report has covered the current short term and long term impact on the market, same will help decision makers to prepare the outline for short term and long term strategies for companies by region. The objective of the report is to present comprehensive Global Monoclonal Antibodies (mAbs) Market including all the stakeholders of the industry. The past and current status of the industry with forecasted market size and trends are presented in the report with analysis of complicated data in simple language. The report covers all the aspects of industry with dedicated study of key players that includes market leaders, followers and new entrants by region. PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors by region on the market have been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give clear futuristic view of the industry to the decision makers. The report also helps in understanding North America for Asia Pacific dynamics, structure by analyzing the market segments, and project the North America for Asia Pacific size. Clear representation of competitive analysis of key players by type, price, financial position, product portfolio, growth strategies, and regional presence in the North America for Asia Pacific make the report investor’s guide.
Scope of the Global Monoclonal Antibodies (mAbs) Market: Inquire before buying
Global Monoclonal Antibodies (mAbs) Market Report Coverage Details Base Year: 2022 Forecast Period: 2023-2029 Historical Data: 2017 to 2022 Market Size in 2022: US $ 180.12 Bn. Forecast Period 2023 to 2029 CAGR: 7% Market Size in 2029: US $ 289.24 Bn. Segments Covered: by Source Type o Murine o Chimeric o Humanized o Human by Production Type o In Vivo o In Vitro by Indications oCancer o Autoimmune Diseases o Inflammatory Diseases o Infectious Diseases o Microbial Diseases o Others by End-User o Hospitals o Research Institutes o Others Monoclonal Antibodies (mAbs) Market, by Region
• North America (United States, Canada and Mexico) • Europe (UK, France, Germany, Italy, Spain, Sweden, Austria and Rest of Europe) • Asia Pacific (China, South Korea, Japan, India, Australia, Indonesia, Malaysia, Vietnam, Taiwan, Bangladesh, Pakistan and Rest of APAC) • Middle East and Africa (South Africa, GCC, Egypt, Nigeria and Rest of ME&A) • South America (Brazil, Argentina Rest of South America)Monoclonal Antibodies (mAbs) Market Key Players are:
• Novartis AG • Pfizer, Inc • GlaxoSmithKline plc • Amgen, Inc. • Merck & Co., Inc • Daiichi Sankyo Company, Ltd. • Abbott • AstraZeneca • Eli Lilly • Johnson & Johnson Services, Inc. • Bayer AG • Bristol Myers Squibb Co. • Mylan N.V. • Biogen Inc. • Thermo Fisher Scientific, Inc. • Novo Nordisk A/S • Sanofi Genzyme • F. Hoffmann-La Roche Ltd. • Cardinal Health Inc. • DTR Medical Frequently Asked questions 1. Which region has the largest share in Global Monoclonal Antibodies (mAbs) Market? Ans: Asia Pacific region held the highest share in 2022. 2. What is the growth rate of Global Monoclonal Antibodies (mAbs) Market? Ans: The Global Monoclonal Antibodies (mAbs) Market is growing at a CAGR of 7% during forecasting period 2023-2029. 3. What is scope of the Global Monoclonal Antibodies (mAbs) Market report? Ans: Global Monoclonal Antibodies (mAbs) Market report helps with the PESTEL, PORTER, COVID-19 Impact analysis, Recommendations for Investors & Leaders, and market estimation of the forecast period. 4. Who are the key players in Global Monoclonal Antibodies (mAbs) Market? Ans: The important key players in the Global Monoclonal Antibodies (mAbs) Market are – Novartis AG,Pfizer, Inc,GlaxoSmithKline plc,Amgen, Inc.,Merck & Co., Inc,Daiichi Sankyo Company, Ltd.,Abbott,AstraZeneca,Eli Lilly,Johnson & Johnson Services, Inc.,Bayer AG. 5. What is the study period of this Market? Ans: The Global Monoclonal Antibodies (mAbs) Market is studied from 2022 to 2029.
Global Monoclonal Antibodies (mAbs) Market
Chapter 1 Research Methodology 1.1. Research Methodology 1.2. Market definition 1.3. Assumptions and Acronyms Used 1.4. Data Sources 1.4.1. Secondary 1.4.1.1. Paid 1.4.1.2. Unpaid 1.4.2. Primary Chapter 2 Executive Summary 2.1. Global Monoclonal Antibodies Market overview 2.1.1. By Source Type 2.1.2. By Production Type 2.1.3. By Indication 2.1.4. By End User Chapter 3 Global Monoclonal Antibodies Market Industry Insights 3.1. Market segmentation and scope of study 3.2. Market Drivers and their impact analysis 3.2.1. Market Drivers 3.2.1.1. Increasing incidences of cancer 3.2.1.2. Rapid technological advancements 3.2.2. Market Restrains 3.2.2.1. Unawareness for the diagnosis of chronic diseases 3.3. Market share analysis 3.3.1. By Source Type 3.3.2. By Production Type 3.3.3. By Indication 3.3.4. By End User 3.4. Competitive analysis 3.4.1. Key strategic initiatives 3.4.2. Regional presence 3.4.3. Product overview 3.5. Porter’s analysis 3.6. PESTEL analysis Chapter 4 Monoclonal Antibodies Market, By Production Type 4.1. Key segment trends 4.2. In Vivo 4.2.1. Market size, by region, 2022-2029 4.3. In Vitro 4.3.1. Market size, by region, 2022-2029 4.3.2. Key Trends in Global Monoclonal Antibodies Market Chapter 5 Monoclonal Antibodies Market, By Source Type 5.1. Key segment trends 5.2. Murine 5.2.1. Market size, by region, 2022-2029 5.3. Chimeric 5.3.1. Market size, by region, 2022-2029 5.4. Humanized 5.4.1. Market size, by region, 2022-2029 5.5. Human 5.5.1. Market size, by region, 2022-2029 Chapter 6 Monoclonal Antibodies Market, By Indications 6.1. Key segment trends 6.2. Cancer 6.2.1. Market size, by region, 2022-2029 6.3. Autoimmune Diseases 6.3.1. Market size, by region, 2022-2029 6.4. Inflammatory Diseases 6.4.1. Market size, by region, 2022-2029 6.5. Infectious Diseases 6.5.1. Market size, by region, 2022-2029 6.6. Microbial Diseases 6.6.1. Market size, by region, 2022-2029 6.1. Others 6.1.1. Market size, by region, 2022-2029 Chapter 7 Monoclonal Antibodies Market, By End-User 7.1. Key segment trends 7.2. Hospitals 7.2.1. Market size, by region, 2022-2029 7.3. Research Institutes 7.3.1. Market size, by region, 2022-2029 7.4. Others 7.4.1. Market size, by region, 2022-2029 Chapter 8 Monoclonal Antibodies Market, By Region 8.1. Key regional trends 8.2. North America 8.2.1. Market size, by country, 2022-2029 8.2.2. Market size, by production type, 2022-2029 8.2.3. Market size, by source type, 2022-2029 8.2.4. Market size, by indications, 2022-2029 8.2.5. Market size, by end-user, 2022-2029 8.2.6. U.S. 8.2.6.1. Market size, by production type, 2022-2029 8.2.6.2. Market size, by source type, 2022-2029 8.2.6.3. Market size, by indications, 2022-2029 8.2.6.4. Market size, by end-user, 2022-2029 8.2.7. Canada 8.2.7.1. Market size, by production type, 2022-2029 8.2.7.2. Market size, by source type, 2022-2029 8.2.7.3. Market size, by indications, 2022-2029 8.2.7.4. Market size, by end-user, 2022-2029 8.3. Europe 8.3.1. Market size, by country, 2022-2029 8.3.2. Market size, by production type, 2022-2029 8.3.3. Market size, by source type, 2022-2029 8.3.4. Market size, by indications, 2022-2029 8.3.5. Market size, by end-user, 2022-2029 8.3.6. Germany 8.3.6.1. Market size, by production type, 2022-2029 8.3.6.2. Market size, by source type, 2022-2029 8.3.6.3. Market size, by indications, 2022-2029 8.3.6.4. Market size, by end-user, 2022-2029 8.3.7. UK 8.3.7.1. Market size, by production type, 2022-2029 8.3.7.2. Market size, by source type, 2022-2029 8.3.7.3. Market size, by indications, 2022-2029 8.3.7.4. Market size, by end-user, 2022-2029 8.3.8. France 8.3.8.1. Market size, by production type, 2022-2029 8.3.8.2. Market size, by source type, 2022-2029 8.3.8.3. Market size, by indications, 2022-2029 8.3.8.4. Market size, by end-user, 2022-2029 8.3.9. Spain 8.3.9.1. Market size, by production type, 2022-2029 8.3.9.2. Market size, by source type, 2022-2029 8.3.9.3. Market size, by indications, 2022-2029 8.3.9.4. Market size, by end-user, 2022-2029 8.3.10. Italy 8.3.10.1. Market size, by production type, 2022-2029 8.3.10.2. Market size, by source type, 2022-2029 8.3.10.3. Market size, by indications, 2022-2029 8.3.10.4. Market size, by end-user, 2022-2029 8.4. Asia Pacific 8.4.1. Market size, by country, 2022-2029 8.4.2. Market size, by production type, 2022-2029 8.4.3. Market size, by source type, 2022-2029 8.4.4. Market size, by indications, 2022-2029 8.4.5. Market size, by end-user, 2022-2029 8.4.6. India 8.4.6.1. Market size, by production type, 2022-2029 8.4.6.2. Market size, by source type, 2022-2029 8.4.6.3. Market size, by indications, 2022-2029 8.4.6.4. Market size, by end-user, 2022-2029 8.4.7. China 8.4.7.1. Market size, by production type, 2022-2029 8.4.7.2. Market size, by source type, 2022-2029 8.4.7.3. Market size, by indications, 2022-2029 8.4.7.4. Market size, by end-user, 2022-2029 8.4.8. Japan 8.4.8.1. Market size, by production type, 2022-2029 8.4.8.2. Market size, by source type, 2022-2029 8.4.8.3. Market size, by indications, 2022-2029 8.4.8.4. Market size, by end-user, 2022-2029 8.4.9. Australia 8.4.9.1. Market size, by production type, 2022-2029 8.4.9.2. Market size, by source type, 2022-2029 8.4.9.3. Market size, by indications, 2022-2029 8.4.9.4. Market size, by end-user, 2022-2029 8.5. Latin America 8.5.1. Market size, by country, 2022-2029 8.5.2. Market size, by production type, 2022-2029 8.5.3. Market size, by source type, 2022-2029 8.5.4. Market size, by indications, 2022-2029 8.5.5. Market size, by end-user, 2022-2029 8.5.6. Argentina 8.5.6.1. Market size, by production type, 2022-2029 8.5.6.2. Market size, by source type, 2022-2029 8.5.6.3. Market size, by indications, 2022-2029 8.5.6.4. Market size, by end-user, 2022-2029 8.5.7. Brazil 8.5.7.1. Market size, by production type, 2022-2029 8.5.7.2. Market size, by source type, 2022-2029 8.5.7.3. Market size, by indications, 2022-2029 8.5.7.4. Market size, by end-user, 2022-2029 8.5.8. Mexico 8.5.8.1. Market size, by production type, 2022-2029 8.5.8.2. Market size, by source type, 2022-2029 8.5.8.3. Market size, by indications, 2022-2029 8.5.8.4. Market size, by end-user, 2022-2029 8.6. Middle East and Africa 8.6.1. Market size, by country, 2022-2029 8.6.2. Market size, by production type, 2022-2029 8.6.3. Market size, by source type, 2022-2029 8.6.4. Market size, by indications, 2022-2029 8.6.5. Market size, by end-user, 2022-2029 8.6.6. South Africa 8.6.6.1. Market size, by production type, 2022-2029 8.6.6.2. Market size, by source type, 2022-2029 8.6.6.3. Market size, by indications, 2022-2029 8.6.6.4. Market size, by end-user, 2022-2029 8.6.7. Saudi Arabia 8.6.7.1. Market size, by production type, 2022-2029 8.6.7.2. Market size, by source type, 2022-2029 8.6.7.3. Market size, by indications, 2022-2029 8.6.7.4. Market size, by end-user, 2022-2029 Chapter 9 Consolidations 9.1. Mergers and Acquisitions 9.2. Partnership, Joint Ventures and Strategic Alliances/Sales Agreements 9.3. Patent Analysis 9.4. Key players 9.4.1. Novartis AG 9.4.1.1. Company overview 9.4.1.2. Key financials 9.4.1.3. Product landscape 9.4.1.4. Strategic initiatives 9.4.1.5. SWOT analysis 9.4.2. Pfizer, Inc 9.4.3. GlaxoSmithKline plc 9.4.4. Amgen, Inc. 9.4.5. Merck & Co., Inc 9.4.6. Daiichi Sankyo Company, Ltd. 9.4.7. Abbott 9.4.8. AstraZeneca 9.4.9. Eli Lilly 9.4.10. Johnson & Johnson Services, Inc. 9.4.11. Bayer AG 9.4.12. Bristol Myers Squibb Co. 9.4.13. Mylan N.V. 9.4.14. Biogen Inc. 9.4.15. Thermo Fisher Scientific, Inc. 9.4.16. Novo Nordisk A/S 9.4.17. Sanofi Genzyme 9.4.18. F. Hoffmann-La Roche Ltd. 9.4.19. Cardinal Health Inc. 9.4.20. DTR Medical